235 related articles for article (PubMed ID: 37716332)
1. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract][Full Text] [Related]
2. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.
Ditonno F; Bianchi A; Malandra S; Porcaro AB; Fantinel E; Negrelli R; Ferro M; Milella M; Brunelli M; Autorino R; Cerruto MA; Veccia A; Antonelli A
Clin Genitourin Cancer; 2024 Apr; 22(2):402-412.e17. PubMed ID: 38281877
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
5. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
Su CT; Nizialek E; Berchuck JE; Vlachostergios PJ; Ashkar R; Sokolova A; Barata PC; Aggarwal RR; McKay RR; Agarwal N; McClure HM; Nafissi N; Bryce AH; Sartor O; Sayegh N; Cheng HH; Adra N; Sternberg CN; Taplin ME; Cieslik M; Alva AS; Antonarakis ES
Prostate; 2023 Feb; 83(3):227-236. PubMed ID: 36382533
[TBL] [Abstract][Full Text] [Related]
6. Differential Activity of PARP Inhibitors in
Taza F; Holler AE; Fu W; Wang H; Adra N; Albany C; Ashkar R; Cheng HH; Sokolova AO; Agarwal N; Kessel A; Bryce A; Nafissi N; Barata P; Sartor AO; Bastos D; Smaletz O; Berchuck JE; Taplin ME; Aggarwal R; Sternberg CN; Vlachostergios PJ; Alva AS; Su C; Marshall CH; Antonarakis ES
JCO Precis Oncol; 2021; 5():. PubMed ID: 34778690
[TBL] [Abstract][Full Text] [Related]
7. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
8. Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Rizzo A; Mollica V; Merler S; Morelli F; Sorgentoni G; Oderda M; Santoni M; Massari F
Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):235-240. PubMed ID: 35485878
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
10. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-ribose) Polymerase Inhibitors Have Comparable Efficacy with Platinum Chemotherapy in Patients with BRCA-positive Metastatic Castration-resistant Prostate Cancer. A Systematic Review and Meta-analysis.
Fazekas T; Széles ÁD; Teutsch B; Csizmarik A; Vékony B; Kói T; Ács N; Hegyi P; Hadaschik B; Nyirády P; Szarvas T
Eur Urol Oncol; 2023 Sep; ():. PubMed ID: 37722977
[TBL] [Abstract][Full Text] [Related]
12. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
13. Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
Aldea M; Lam L; Orillard E; Llacer Perez C; Saint-Ghislain M; Gravis G; Fléchon A; Roubaud G; Barthelemy P; Ricci F; Priou F; Neviere Z; Beaufils M; Laguerre B; Hardy AC; Helissey C; Ratta R; Borchiellini D; Pobel C; Joly F; Castro E; Thiery-Vuillemin A; Baciarello G; Fizazi K
Eur J Cancer; 2021 Dec; 159():87-97. PubMed ID: 34742160
[TBL] [Abstract][Full Text] [Related]
14. Review of Toxicities of PARP Inhibitors in Metastatic Castrate Resistant Prostate Cancer.
Nindra U; Hong JH; Balakrishnar B; Pal A; Chua W
Clin Genitourin Cancer; 2023 Feb; 21(1):183-193. PubMed ID: 35927195
[TBL] [Abstract][Full Text] [Related]
15. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
16. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
17. Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
Yap TA; Bardia A; Dvorkin M; Galsky MD; Beck JT; Wise DR; Karyakin O; Rubovszky G; Kislov N; Rohrberg K; Joy AA; Telli ML; Schram AM; Conte U; Chappey C; Stewart R; Stypinski D; Michelon E; Cesari R; Konstantinopoulos PA
JAMA Oncol; 2023 Jan; 9(1):40-50. PubMed ID: 36394849
[TBL] [Abstract][Full Text] [Related]
18. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
[TBL] [Abstract][Full Text] [Related]
19. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Sayyid RK; Klaassen Z; Berlin A; Roy S; Brandão LR; Bernardino R; Chavarriaga J; Jiang DM; Spratt DE; Fleshner NE; Wallis CJD
BJU Int; 2023 Dec; 132(6):619-630. PubMed ID: 37461140
[TBL] [Abstract][Full Text] [Related]
20. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
